Institute of Oncology Research (IOR)
Projects
In progress (20)
- Theurillat J. P. (2024) Translational Prostate Cancer Symposium: Horizons in Prostate Cancer Research
- Theurillat J. P. (2024) Mining and Predicting Prostate Cancer Progression for Better Patient Care
- Theurillat J. P. (2024) PCaMiner - Prototyping the harmonization and the integrated mining of prostate cancer RNA se-quencing data sets
- Zucca E. (2024) Multilayer taxonomy of nodal marginal zone lymphoma
- Calcinotto A. (2024) Exploiting neutrophil heterogeneity as mediator of synthetic lethality in breast cancer
- Calcinotto A. (2024) 218488 - Dissecting the role of intracellular bacteria and neutrophil heterogeneity in cancer susceptibility and progression
- Alimonti A. (2024) Development of a drug discovery platform to identify microbiome-derived therapeutics
- Alimonti A. (2023) Microbiota regulation of prostate cancer growth and metastatic dissemination
- Baggiolini A. (2023) Oncogenic Competence at the Cellular and Multicellular Level in Melanoma
- Baggiolini A. (2023) Human pluripotent stem cell-derived model of perineural tumor microenvironment
- Carbone G. (2023) Novel epigenetic players in castration-resistant prostate cancer: functional and therapeutic impact
- Theurillat J. P. (2022) Transcriptome-Guided Reverse Engineering of Human Prostate Cancer
- Catapano C. (2022) Liver-specific inhibition of Lin28B for treatment of hepatocarcinoma
- Alimonti A. (2022) Optimisation of therapies targeting the gut microbiota in prostate cancer
- Rossi D. (2022) Understanding how clonal hematopoiesis feeds lymphoma
- Alimonti A., Barile L., Cippà P. (2021) Targeting cellular senescence in physiological, pathological and iatrogenic conditions
- Alimonti A. (2021) Excellence Grant –Development of senolytic therapies for chemotherapy-treated prostate cancer
- Bertoni F. (2020) Enhancer RNAs in B cell lymphomas
- Theurillat J. P. (2020) Deciphering the Biology and the Therapeutic Implications of SPOP Mutant Prostate Cancer
- Rossi D. (2020) Discovery of genetic/epigenetic addictions in NOTCH2/KLF2-mutated lymphoma
Completed (41)
- Alimonti A. (2023) New frontiers in biological and environmental determinants of aging
- Rossi D., Zucca E. (2023) The Lugano classification for staging and response assessment of lymphoma: Looking towards the future
- Geiger R., Catapano C., Cejka P., Sallusto F., Theurillat J. P. (2022) timsTOF Pro 2 for clinical proteomics
- Rossi D. (2022) Uncovering the pathophysiology and vulnerability of minimal residual disease persisting under venetoclax in patients with chronic lymphocytic leukemia
- Alimonti A. (2022) Development of a senolytic of natural origin for antiaging therapy
- Bertoni F. (2021) Evaluation of non-ATP competitive PI3K# inhibition with IOA-244 in the treatment of lymphoma
- Alimonti A. (2020) Development of a senolytic of natural origin for anti-aging therapy
- Bertoni F. (2020) Anti-L1CAM antibody therapy for rare diseases
- Bertoni F. (2020) Development of a microfluidic platform for real-time detection of SARS-CoV-2 virus based on multifunctional silica membrane biosensors
- Napoli N. (2020) Characterization of specific enhancer RNAs involved in ibrutinib resistance mechanism in marginal zone lymphoma
- Catapano C. (2020) Nanoparticle-based delivery and combinatorial therapies for cancer
- Alimonti A., Calcinotto A., Catapano C., Iezzi G., Rossi D. (2019) High parameter cell analysis by BD FACSymphony
- Gaudio E. (2019) A novel combined approach of nuclear magnetic resonance (NMR) and Mass spectrometry to isolate the protein targets of chemical small molecules.
- Carbone G. (2019) The ETS transcription factor ESE3/EHF as a regulator of prostate epithelial cell differentiation and stem cell properties
- Theurillat J. P. (2019) Deciphering and Targeting the Cancer Ubiquitylome
- Rossi D. (2019) Bridging liquid biopsy into management of lymphoma patients: development of frameworks for clinical research and recommendations for clinical practice
- Alimonti A. (2018) Development of senolytic therapies for chemotherapy-treated prostate cancer
- Theurillat J. P. (2018) Understanding Synthetic Sick Interactions of Prostate Cancer Driver Genes
- Rossi D. (2018) CLLCLONE - Harnessing clonal evolution in chronic lymphocytic leukemia
- Zucca E., Rossi D. (2018) IELSG46 - Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma
- Theurillat J. P. (2017) Development of predictive pre-clinical cell culture models for prostate cancer
- Catapano C. (2017) Targeting metabolic reprogramming and plasticity of cancer stem cells to impact on tumor progression and treatment resistance
- Catapano C. (2017) Epigenetic cross-talks and novel therapeutic strategies to prevent disease progression in ERG fusion positive prostate cancer
- Rossi D. (2017) Molecular prediction of long term benefit from ibrutinib in high risk chronic lymphocytic leukemia
- Carbone G. (2016) The ETS transcription factor ESE3/EHF as a regulator of prostate epithelial cell differentiation and stem cell properties
- Alimonti A. (2016) Immune-senescence - Dual targeting of senescence and tumor immunity for cancer therapy
- Bertoni F., Zucca E. (2016) Targeted agents in splenic marginal zone lymphoma: mechanisms of resistance and new combinations
- Theurillat J. P. (2014) Genetically-Induced Aberrant Chromatin States in Prostate Cancer – Biology and Therapy
- Catapano C., Carbone G. (2014) Promoter-proximal long non-coding RNAs and epigenetic regulatory networks in prostate cancer
- Bertoni F. (2014) Functional analysis of altered transcriptional pathways in diffuse large B-cell lymphoma of the ABC subtype
- Kwee I., Bertoni F. (2013) Steiner Trees for Functional Analysis in Cancer System Biology
- Carbone G. (2013) The ETS transcription factor ESE3/EHF as a regulator of prostate epithelial cell differentiation and stem cell properties
- Alimonti A. (2012) Manipulation of senescence pathways for cancer therapy: from experimental models to clinic
- Alimonti A. (2011) Manipulation of senescence pathways for cancer therapy: from experimental models to clinic
- Catapano C. (2010) DENANORNA - Dendrimers as nanovectors for targeted siRNA delivery in gene therapy
- Catapano C. (2009) Small RNA-based transcriptional control of cancer genes
- Kwee I., Bertoni F. (2008) A Bayesian Approach for Integrated Cancer Genome Profiling 2
- Carbone G., Bertoni F., Catapano C. (2007) The epithelial specific ETS transcription factor-3 as a tumor suppressor in prostate cancer
- Kwee I., Bertoni F. (2007) A Bayesian Approach for Integrated Cancer Genome Profiling
- Catapano C. (2006) Gene selective transcriptional repression by antigene oligonucleotides
- Pagani Santoro O. (2004) Translating molecular knowledge into early breast cancer management: building on the BIG (Breast International Group) network for improved treatment tailoring - TRANS-BIG
